TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

17.9255 USD
+0.05 (+0.25%)
Last: Mar 9, 2026, 02:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

TAK gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While TAK belongs to the best of the industry regarding profitability, there are concerns on its financial health. TAK has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • TAK had positive earnings in the past year.
  • In the past year TAK had a positive cash flow from operations.
  • TAK had positive earnings in each of the past 5 years.
  • Each year in the past 5 years TAK had a positive operating cash flow.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • The Return On Assets of TAK (0.73%) is better than 80.31% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.48%, TAK belongs to the top of the industry, outperforming 82.38% of the companies in the same industry.
  • TAK's Return On Invested Capital of 2.32% is fine compared to the rest of the industry. TAK outperforms 79.79% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for TAK is significantly below the industry average of 13.08%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • With an excellent Profit Margin value of 2.53%, TAK belongs to the best of the industry, outperforming 81.35% of the companies in the same industry.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • TAK's Operating Margin of 10.76% is amongst the best of the industry. TAK outperforms 83.42% of its industry peers.
  • In the last couple of years the Operating Margin of TAK has grown nicely.
  • TAK has a Gross Margin of 65.33%. This is in the better half of the industry: TAK outperforms 74.09% of its industry peers.
  • TAK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), TAK is creating some value.
  • The number of shares outstanding for TAK has been increased compared to 1 year ago.
  • The number of shares outstanding for TAK has been increased compared to 5 years ago.
  • The debt/assets ratio for TAK has been reduced compared to a year ago.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • Based on the Altman-Z score of 1.22, we must say that TAK is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of 1.22, TAK perfoms like the industry average, outperforming 58.55% of the companies in the same industry.
  • The Debt to FCF ratio of TAK is 6.48, which is on the high side as it means it would take TAK, 6.48 years of fcf income to pay off all of its debts.
  • TAK's Debt to FCF ratio of 6.48 is amongst the best of the industry. TAK outperforms 82.38% of its industry peers.
  • TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
  • TAK has a Debt to Equity ratio of 0.56. This is in the lower half of the industry: TAK underperforms 63.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.22
ROIC/WACC1.41
WACC1.64%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that TAK should not have too much problems paying its short term obligations.
  • TAK has a worse Current ratio (1.19) than 77.20% of its industry peers.
  • A Quick Ratio of 0.65 indicates that TAK may have some problems paying its short term obligations.
  • TAK's Quick ratio of 0.65 is on the low side compared to the rest of the industry. TAK is outperformed by 85.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • The earnings per share for TAK have decreased strongly by -45.17% in the last year.
  • Measured over the past years, TAK shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.20% on average per year.
  • Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
  • TAK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.84% yearly.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • Based on estimates for the next years, TAK will show a very strong growth in Earnings Per Share. The EPS will grow by 45.92% on average per year.
  • The Revenue is expected to grow by 0.20% on average over the next years.
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 77.94, TAK can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, TAK is valued a bit cheaper than the industry average as 77.20% of the companies are valued more expensively.
  • TAK is valuated expensively when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • TAK is valuated quite expensively with a Price/Forward Earnings ratio of 30.29.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TAK indicates a somewhat cheap valuation: TAK is cheaper than 73.06% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.60, TAK is valued a bit more expensive.
Industry RankSector Rank
PE 77.94
Fwd PE 30.29
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 87.56% of the companies listed in the same industry.
  • 88.60% of the companies in the same industry are more expensive than TAK, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.94
EV/EBITDA 10.51
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • TAK's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • TAK's earnings are expected to grow with 45.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.05
PEG (5Y)4.06
EPS Next 2Y65.4%
EPS Next 3Y45.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • TAK has a Yearly Dividend Yield of 3.55%.
  • TAK's Dividend Yield is rather good when compared to the industry average which is at 0.70. TAK pays more dividend than 95.34% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, TAK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.55%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has paid a dividend for at least 10 years, which is a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • 277.04% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
  • TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP277.04%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (3/9/2026, 2:37:33 PM)

17.9255

+0.05 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners47.91%
Inst Owner Change-0.91%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap56.63B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target18.18 (1.42%)
Short Float %0.21%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield 3.55%
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)3.21%
PT rev (3m)11.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-370.39%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)1.66%
Revenue NQ rev (3m)3.1%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 77.94
Fwd PE 30.29
P/S 2
P/FCF 11.94
P/OCF 7.52
P/B 1.17
P/tB N/A
EV/EBITDA 10.51
EPS(TTM)0.23
EY1.28%
EPS(NY)0.59
Fwd EY3.3%
FCF(TTM)1.5
FCFY8.37%
OCF(TTM)2.38
OCFY13.3%
SpS8.95
BVpS15.32
TBVpS-3.26
PEG (NY)1.05
PEG (5Y)4.06
Graham Number8.9
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.22
F-Score5
WACC1.64%
ROIC/WACC1.41
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year436.14%
EBIT Next 3Y77.24%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


What is the profitability of TAK stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for TAK stock?

The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 77.94 and the Price/Book (PB) ratio is 1.17.


How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?

The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.